ClinicalTrials.gg
RecruitingNCT07409727Updated Jul 10, 2026

Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients

A Phase 4 interventional study of Acetyl cysteine and Normal (0.9%) saline in Ventilation Acquired Pneumonia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Cairo University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pneumonia by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Pneumonia · Cairo University.

Planned enrollment
3rd of 11
80 · median 60
Started
2026
the only one that year
Phase 4
Only one
of the 13
Registered
13th of 13
by date

Among the 13 studies in Pneumonia by Cairo University, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 4, and was the 13th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

4 of the 13 studies in Pneumonia by Cairo University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pneumonia by Cairo University, or all of them as a file.
02

Study summary

Background Mechanical ventilation is an essential medical intervention in the context of critical illness. However, the intervention is associated with a risk of significant, potentially preventable complications. Among these are ventilator-associated pneumonia, sepsis, acute respiratory distress syndrome, atelectasis, and pulmonary edema.

Ventilator-associated complications commonly increase morbidity and mortality. They may also prolong the duration of mechanical ventilation and the length of stay in the hospital or the intensive care unit, with increased health care costs; so safe, effective therapeutic and preventative strategies are essential to attenuate poor outcomes from ventilator-associated events.

Secretion retention and ineffective cough play a significant role in failed extubation and weaning from ventilator; the presence of the artificial airway, poor humidification of inspired gases, and immobility are the major causes of pulmonary secretion retention in this population. Accumulated secretion in the airways, if extensive, starts a self-sustaining cycle of ventilation/perfusion mismatch, gas-exchange impairment, increased work of breathing.

For decades N-acetyl-L-cysteine (NAC) has been used for its mucolytic properties orally in different respiratory diseases like chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF); but its effects are not known if given by nebulization through endotracheal tube (ETT), studies to date have provided inconclusive results. Despite this uncertainty, mucoactive agents are still used in adult ICUs.

NAC is usually administered orally, with several formulations and dosage forms available for both short- and long-term treatment of respiratory diseases. The inhalation route might also be considered a practical option, with recent interest, as the therapeutic drug acts directly on the bronchial mucosa, promotes continuous local retention of the drug, prolongs anti-inflammatory effects, and avoids the liver first-pass effect, which can help quickly improve airway inflammation.

Contrary to other mucoactive drugs, NAC has been found to exhibit antioxidant, anti-inflammatory, antibacterial, and antibiofilm activities.

In the respiratory infection field, the available data indicate that NAC was associated with inhibition of oxidative stress and reduced the inflammatory factors in community acquired pneumonia, antibiofilm activity specially in pseudomonas aeruginosa infection in pre-clinical and clinical reports and has good antibacterial properties and suggested to interfere with biofilm formation and disruption.

NAC has shown improvement in the respiratory index (PaO₂/FiO₂), with lower rates of mechanical ventilation in COVID-19. When studied in mechanically ventilated patients with acute respiratory distress syndrome (ARDS), which is associated with oxidative stress, increased levels of glutathione, and inflammation, NAC demonstrated improvements in positive end-expiratory pressure (PEEP) and PaO₂/FiO₂.

N-Acetylcysteine contributed to delaying ventilator-associated pneumonia (VAP) in mechanically ventilated patients when administered orally as a preventive medication. It was also effective in attenuating the decline in forced vital capacity (FVC) in mild to moderate idiopathic pulmonary fibrosis (IPF), and it showed a lower rate of postoperative pulmonary complications when given pre-operatively in orthotopic liver transplantation.

Since NAC is relatively low-cost, readily available, and has a favorable side effect profile, it is important to properly assess the clinical benefits of nebulized NAC as an adjunct to standard medical treatments in mechanically ventilated patients.

Aim of the study

This study will assess the role of preventive N-acetylcysteine inhalation on incidence and time to develop VAP in critically ill mechanically ventilated patients.

Objectives

  • 1) Assessment of N-acetylcysteine inhalation efficacy in mechanically ventilated patients through monitoring the following parameters: time to develop ventilator-associated pneumonia (VAP), incidence of VAP, PaO₂/FiO₂, pH, oxygen saturation (SaO₂), peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), frequency of endotracheal tube (ETT) suction and tube exchange, and infection parameters (total leukocyte count, body temperature). In addition, hospital mortality, duration of mechanical ventilation (MV), ventilator-free days, and the length of hospital and ICU stay
  • 2) Assessment of the safety of N-acetylcysteine inhalation in mechanically ventilated patients by monitoring the incidence of new-onset bronchospasm
03

Conditions studied

  • Ventilation Acquired Pneumonia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-64 years, either male or female.
  2. Critically ill patients who have undergone intubation and are on mechanical ventilation.
  3. Expected duration of mechanical ventilation of more than 48 hours.
  4. Provided consent to participate in this clinical trial by next of kin.

Exclusion criteria

Exclusion Criteria:

  1. Patients currently on long-term NAC treatment.
  2. Confirmed brain death.
  3. Recent chest infection.
  4. patients on immunosuppressive medication.
  5. Patients mechanically ventilated in another hospital.
  6. Pregnant women.
  7. Mean arterial pressure (MAP) \<60 mmHg despite adequate resuscitation and vasopressor therapy at the time of randomization.
  8. Known intolerance or to study medication.
  9. Presence of a condition or abnormality that would compromise the quality of the data.

    -

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    40 adult patients receiving 3ml normal saline 0.9% inhalation every 12hrs.

    40 adult patients receiving 3ml normal saline 0.9% inhalation every 12hrs using Aerogen solo nebulizers

    Drug: Normal (0.9%) saline

  • Experimental
    40 adult patients will recieve 3ml acetyl cysteine 10% nebulizer every 12 hrs

    40 adults patients receiving 3ml acetylcysteine inhalation every 12hrs using Aerogen solo nebulizers.

    Drug: Acetyl cysteine

Interventions

  • 40 adult mechanically ventilated patients will receive 3ml acetyl cysteine 10% nebulised every 12 hours .Nebulization will be performed using a vibrating mesh nebulizer ( Aerogen solo) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry.

  • DrugNormal (0.9%) saline

    40 adult mechanically ventilated patients will receive 3ml normal saline nebulised every 12 hours. Nebulization will be performed using a vibrating mesh nebulizer (Aerogen solo) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry

06

What researchers measure

Primary outcomes

  1. The primary endpoint of interest is incidence and time to develop ventilator associated pneumonia.

    1. Incidence of VAP will be expressed as percentage of patients who developed VAP. 2. Time to develop VAP is expressed in days

    Time frame: participant will be followed up for 10 days post mechanical ventilation or till extubation (whichever occurs first).

Secondary outcomes

  1. 1) Infection parameters (TLC,Temperature °C) 2)Change in P/F ratio 3) Duration of mechanical ventilation expressed in days 4) Day 3 ETT aspirate culture positivity 5) Number of endotracheal tube exchange and suctioning episodes per ventilator day.

    1. Change in infection parameter TLC (×10⁹/L), CRP (mg/L), body temperature (°C) from base line to day 10 post intubation or till extubation 2. Change in (P/F ratio measured in mmHg) from baseline to day 10 post intubation or till extubation 3. Positive vs negative ETA culture 4. Incidence and time to develop Ventilator associated tracheobronchitis.

    Time frame: participant will be followed up for 10 days post mechanical ventilation or till extubation (whichever occurs first)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 42 non-industry phase 4 interventional studies under Pneumonia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 43. This study's planned 24 months is below that.

Counting every sponsor, half of 49 studies reached it within 31 months; a quarter within 21 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 13, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 1, 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409727
Lead sponsor
Cairo University
Collaborators
Aerogen
Responsible party
Sarah Rabie Mohamed Adly (clinical pharmacist, Cairo University) — Principal investigator
First posted
Feb 13, 2026
Start date
Mar 1, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Maggie M Abbassi, professor of clinical pharmacy
Contact
Maggie.abbassi@pharma.cu.edu.eg
00201001589925

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion